Agilent Technologies has released a statement reporting that its portfolio of DNA microarrays is now manufactured under ISO 13485 certification, a recognized standard for quality management systems (QMS).
Agilent Technologies has released a statement reporting that its portfolio of DNA microarrays is now manufactured under ISO 13485 certification, a recognized standard for quality management systems (QMS).
Robert Schueren, Agilent vice president and general manager, Genomics and Life Science Reagents, commented, “Agilent has always emphasized quality in the manufacture of microarrays and we’re very pleased to be adding the validation of ISO 13485-registered QMS on top of our existing ISO 9001 standard.”
Additionally, the company is preparing to take the next step in pursuing clearance from the US FDA for a cytogenetics platform, according to vice president and general manager of the Biological Systems division, Gustavo Salem.
For more information on the company and its products visit the website at www.agilent.com
This story originally appeared in The Column. Click here to view that issue.
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.